Icon

OLYSIO (nda205123)- (EQ 150MG BASE)

SIMEPREVIR SODIUM JANSSEN PRODS
EQ 150MG BASE
No No
2029-Sep-05 2018-Nov-22
None None
None No
OLYSIO is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: • in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis • in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis.
0 0 0
Total Other Developers 1
Drugs with Suitability No
EQ 150MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.